Analysts Expect Aptose Biosciences Inc. (NASDAQ:APTO) Will Announce Earnings of -$0.13 Per Share

Wall Street analysts expect that Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) will post earnings of ($0.13) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Aptose Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.14) and the highest estimate coming in at ($0.12). Aptose Biosciences reported earnings per share of ($0.17) during the same quarter last year, which would indicate a positive year-over-year growth rate of 23.5%. The business is expected to issue its next quarterly earnings results on Tuesday, March 10th.

According to Zacks, analysts expect that Aptose Biosciences will report full year earnings of ($0.53) per share for the current fiscal year, with EPS estimates ranging from ($0.55) to ($0.51). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.63) per share, with EPS estimates ranging from ($0.70) to ($0.55). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Aptose Biosciences.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01.

A number of analysts have weighed in on the stock. ValuEngine raised shares of Aptose Biosciences from a “sell” rating to a “hold” rating in a report on Tuesday. Zacks Investment Research cut shares of Aptose Biosciences from a “buy” rating to a “hold” rating in a report on Monday, August 12th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Aptose Biosciences presently has a consensus rating of “Buy” and an average price target of $5.30.

APTO stock traded up $0.21 during midday trading on Thursday, reaching $3.75. 1,740,261 shares of the company were exchanged, compared to its average volume of 360,835. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.83 and a current ratio of 7.83. Aptose Biosciences has a 1-year low of $1.57 and a 1-year high of $3.97. The stock’s 50-day simple moving average is $2.43 and its 200 day simple moving average is $2.37. The company has a market cap of $190.33 million, a price-to-earnings ratio of -4.36 and a beta of 1.75.

Several institutional investors have recently made changes to their positions in the company. Man Group plc increased its holdings in shares of Aptose Biosciences by 8.6% in the 3rd quarter. Man Group plc now owns 1,609,424 shares of the biotechnology company’s stock valued at $3,356,000 after acquiring an additional 127,836 shares during the period. Creative Planning acquired a new position in shares of Aptose Biosciences in the 3rd quarter valued at $156,000. Sigma Planning Corp increased its holdings in shares of Aptose Biosciences by 4.1% in the 3rd quarter. Sigma Planning Corp now owns 228,150 shares of the biotechnology company’s stock valued at $476,000 after acquiring an additional 9,000 shares during the period. P.A.W. Capital Corp acquired a new position in shares of Aptose Biosciences in the 3rd quarter valued at $1,043,000. Finally, Patriot Financial Group Insurance Agency LLC increased its holdings in shares of Aptose Biosciences by 8.2% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 92,029 shares of the biotechnology company’s stock valued at $192,000 after acquiring an additional 7,000 shares during the period. 25.61% of the stock is currently owned by institutional investors and hedge funds.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Featured Article: Initial Coin Offerings entail a high degree of risk

Get a free copy of the Zacks research report on Aptose Biosciences (APTO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.